Company intelligence / Profile preview

EyeControl

Tel Aviv, Tel Aviv District, Israeleyecontrol.co.il ↗

Ownership: Private
Development stage: Commercial

Overview

EyeControl’s core device is CE marked, FDA listed, ISO certified, and reimbursed by major healthcare systems. Early phase I clinical data for the delirium-focused "EyeControl-Pro" show decreased errors on the Confusion Assessment Method for the ICU and improved patient engagement scores.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceDigital health platform (AI-driven patient engagement and communication)
Industry: Assistive Medical Devices

Partnerships

European Commission's Horizon2020 SME Instrument & EIC Accelerator programsU.S. Centers for Medicare & Medicaid Services reimbursement partnerUK National Health Service reimbursement partnerIsraeli Ministry of Health reimbursement partner

Beyond the preview

Go deeper on EyeControl.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeControl.

Explore the full profile